Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Oruka Therapeutics Inc. Common Stock (ORKA) vs VF Corp (VFC) Price & Performance

Oruka Therapeutics Inc. Common StockTrade

Price performance (Past 24H)

Key statistics

Oruka Therapeutics Inc. Common Stock vs VF Corp — how do they compare? Oruka Therapeutics Inc. Common Stock trades at $75.2 (market cap $5.18B), while VF Corp trades at $16.52 (market cap $6.32B). The key difference: VF Corp is the larger of the two by market cap, and VF Corp pays a 2.24% dividend while Oruka Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Oruka Therapeutics Inc. Common Stock for 0 Days and VF Corp for 64 Days on average.

ORKAVFC
Market Cap
$5.18B$6.32B
Volume
490,79814,983,623
Sector
HealthConsumer Cyclical
52-Week High
$113.08$21.55
52-Week Low
$26.19$12.62
Typical Hold Time
0 Days64 Days
Enterprise Value
$4.31B$10.60B
Dividend Yield
—2.24%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Oruka Therapeutics Inc. Common Stock

No Aura AI signal available yet.

VF Corp

VFC trades at $16.48, up 4.37% today, with a bullish technical signal and a consensus analyst price target of $18.33. Recent earnings show mixed results, with a Q4 2025 beat but Q1 and Q2 2026 misses. Revenue declined to $9.5B in 2025, with a net loss of $189.72M, though 2026 projects a return to profitability. The company maintains a strong gross margin of 54.97% but faces challenges from high debt and weak performance in its Vans brand.

The outlook is cautiously optimistic, supported by valuation discounts (P/S 0.67) and growth in outdoor brands, but execution risk on the Vans turnaround and high leverage pose significant threats. Near-term price action is buoyed by technical momentum, yet fundamental recovery hinges on sustained revenue improvement and debt reduction.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

ORKA
100% Buy0% Sell
Avg holding period · 0 Days
VFC
17% Buy83% Sell
Avg holding period · 64 Days

Top news

Latest headlines on both assets

About Oruka Therapeutics Inc. Common Stock

Oruka Therapeutics, Inc. is a clinical-stage biotechnology company developing extended half-life monoclonal antibodies for plaque psoriasis, psoriatic arthritis, and related dermatologic conditions, with lead candidates ORKA-001 and ORKA-002 in clinical trials.

Read more on ORKA →

About VF Corp

VF designs, produces, and distributes branded apparel and accessories. Its largest apparel categories include action sports, outdoor, and workwear. Its portfolio of about a dozen brands includes Vans, The North Face, Timberland, Supreme, and Dickies. VF markets its products in the Americas, Europe, and Asia-Pacific through wholesale sales to retailers, e-commerce, and branded stores owned by the company and partners. The company has grown through multiple acquisitions and traces its roots to 1899.

Read more on VFC →